Journal Mobile Options
Table of Contents
Vol. 98, No. 2, 2004
Issue release date: October 2004
Section title: Paper
Nephron Physiol 2004;98:p43–p47
(DOI:10.1159/000080263)

Osteopontin and Calcium Stone Formation

Kleinman J.G. · Wesson J.A. · Hughes J.
aNephrology Division, Veterans Affairs Medical Center, and Medical College of Wisconsin, Milwaukee, Wisc., USA; bPhagocyte Laboratory, MRC Center for Inflammation Research, University of Edinburgh Medical School, Edinburgh, UK

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 10/19/2004

Number of Print Pages: 1
Number of Figures: 2
Number of Tables: 0

ISSN: (Print)
eISSN: 1660-2137 (Online)

For additional information: http://www.karger.com/NEP

Abstract

Osteopontin (OPN) is a phosphorylated protein of wide tissue distribution that is found in association with dystrophic calcification including in the organic matrix of kidney stones. It is a strong inhibitor of crystal formation and growth in vitro, but there is still debate regarding its effects upon crystal adhesion to tubular epithelial cells. In this brief review, we will outline the evidence implicating OPN in stone disease with the primary emphasis being on the interaction of OPN with calcium oxalate (CaOx), the major constituent of calcium containing stones. Finally, preliminary data is presented regarding the amounts and features of OPN present in the urine of stone formers and normal individuals.


  

Author Contacts

Jack G. Kleinman, MD
Veterans Affairs Medical Center/111K
5000 W. National Avenue
Milwaukee, WI 53925 (USA)
Tel. +1 414 384 2000, ext. 42827, Fax +1 414 383 9333, E-Mail kleinman@mcw.edu

  

Article Information

Number of Print Pages : 5
Number of Figures : 2, Number of Tables : 0, Number of References : 46

  

Publication Details

Nephron Physiology

Vol. 98, No. 2, Year 2004 (Cover Date: October 2004)

Journal Editor: R.J. Unwin, London
ISSN: 0028–2766 (print), 1660–2137 (Online)

For additional information: http://www.karger.com/nep


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 10/19/2004

Number of Print Pages: 1
Number of Figures: 2
Number of Tables: 0

ISSN: (Print)
eISSN: 1660-2137 (Online)

For additional information: http://www.karger.com/NEP


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.